Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicentric Trial to Assess Efficacy and Toxicity of Imatinib in Adult Patients With Metastatic Ocular Melanoma

NCT00421317 is registered in ClinicalTrials.gov with Centre Oscar Lambret as lead sponsor.

NCT NCT00421317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00421317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicentric Trial to Assess Efficacy and Toxicity of Imatinib in Adult Patients With Metastatic Ocular Melanoma
Lead sponsor
Centre Oscar Lambret
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2005
Completion date
November 15, 2009
Enrollment
13 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma